Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $7.70M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 13.24%
• EPS Growth: 98.80%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.19
• Shares Outstanding: 4,555,945
• 10 Day Avg. Volume: 3,175,467
• 30 Day Avg. Volume: 1,091,586
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.06
• P/FCF Ratio: -0.14
• Enterprise Value/Market Cap: -0.38
• Enterprise Value/Revenue: -0.08
• Enterprise Value/Gross Profit: -0.24
• Enterprise Value/Ebitda: 0.47
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.50 ▲(7.14% Upside)

Sunshine Biopharma's overall stock score is primarily impacted by its financial performance and technical analysis. The company shows strong revenue growth but struggles with profitability and cash flow management, leading to a low financial performance score. Technical indicators suggest bearish momentum, further weighing down the score. The negative P/E ratio and lack of dividend yield reflect valuation challenges. Without earnings call insights or notable corporate events, these factors dominate the overall assessment.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and demand for SBFM's products, supporting long-term business expansion.

Low Leverage

Low leverage enhances financial stability and flexibility, allowing SBFM to invest in growth opportunities without significant debt burden.

Innovative Product Pipeline

A strong focus on innovation in cancer therapies positions SBFM to capture market share in unmet medical needs, driving future growth.

Negative Factors

Profitability Challenges

Persistent profitability issues can hinder SBFM's ability to reinvest in R&D and growth, impacting long-term competitiveness.

Cash Flow Issues

Negative cash flows limit SBFM's operational flexibility and ability to fund new projects, posing a risk to sustainable growth.

Negative Returns on Equity

Negative ROE indicates inefficiencies in generating profits from shareholders' equity, which can deter investment and affect growth.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates in the biotechnology sector, specializing in the research, development, and commercialization of novel drug candidates. SBFM's core products include proprietary compounds targeting various types of cancers, with an emphasis on addressing unmet medical needs through advanced therapeutic solutions.

How the Company Makes Money

Sunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company may earn revenue through several key streams, including licensing agreements, partnerships with larger pharmaceutical firms for joint development efforts, and potential sales of its drug candidates upon successful regulatory approval. Additionally, SBFM may seek funding through grants or investments that support its research initiatives. Significant partnerships with research institutions or pharmaceutical companies can also enhance its revenue potential by providing access to additional resources, expertise, and markets.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma shows strong revenue growth but struggles with profitability, as indicated by negative net profit and EBIT margins. The balance sheet is stable with low leverage, but negative returns on equity highlight ongoing financial struggles. Cash flow issues persist, with negative operating and free cash flows, indicating liquidity concerns.

Income Statement

Sunshine Biopharma has shown significant revenue growth in recent periods, particularly with a 29.6% increase in TTM. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin is stable but not sufficient to cover operating expenses, leading to consistent net losses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is reasonable, suggesting a stable asset base relative to equity.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite this, the free cash flow to net income ratio suggests some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.34M	34.87M	24.09M	4.35M	228.43K	71.41K
Gross Profit	12.11M	10.67M	8.34M	1.70M	110.60K	45.56K
EBITDA	-6.19M	-5.15M	-3.82M	-26.45M	-12.10M	-2.60M
Net Income	-6.31M	-5.13M	-4.51M	-26.74M	-12.44M	-2.78M
Balance Sheet
Total Assets	31.97M	30.56M	27.35M	29.55M	2.20M	1.05M
Cash, Cash Equivalents and Short-Term Investments	10.31M	9.69M	16.29M	21.83M	2.05M	997.48K
Total Debt	929.03K	952.48K	657.71K	765.26K	1.90M	1.91M
Total Liabilities	6.28M	7.06M	6.14M	7.92M	1.99M	2.00M
Stockholders Equity	25.68M	23.50M	21.21M	21.63M	211.66K	-954.84K
Cash Flow
Free Cash Flow	-9.47M	-14.85M	-9.56M	-5.55M	-1.83M	-658.49K
Operating Cash Flow	-7.76M	-12.53M	-8.78M	-5.25M	-1.83M	-657.30K
Investing Cash Flow	-1.78M	-2.32M	-656.15K	-14.62M	0.00	-1.19K
Financing Cash Flow	7.87M	9.29M	3.43M	39.47M	2.90M	1.61M

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.4 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 1.66, and below the 200-day MA of 1.65, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 32.20 is Neutral, neither overbought nor oversold. The STOCH value of 21.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVOK	46 Neutral	$16.61M	-3.72	-134.88%	―	67.40%	78.51%
IMCC	42 Neutral	$6.72M	-2.36	-93.87%	―	-0.74%	81.49%
SNOA	41 Neutral	$6.20M	-1.53	-76.14%	―	25.02%	55.11%
SBFM	41 Neutral	$7.70M	-0.65	-24.34%	―	13.24%	98.80%
YCBD	40 Underperform	$7.21M	-0.13	-33.13%	―	-7.80%	90.17%
SHPH	32 Underperform	$2.16M	―	-9999.00%	―	―	79.31%